Evolent Health, Inc $EVH Stake Reduced by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC decreased its holdings in shares of Evolent Health, Inc (NYSE:EVH) by 56.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,825 shares of the technology company’s stock after selling 20,865 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Evolent Health were worth $178,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in EVH. Banque Cantonale Vaudoise acquired a new stake in Evolent Health during the first quarter valued at approximately $25,000. Nisa Investment Advisors LLC increased its holdings in shares of Evolent Health by 88.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock valued at $29,000 after buying an additional 1,194 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of Evolent Health by 82.6% during the 2nd quarter. Parallel Advisors LLC now owns 3,487 shares of the technology company’s stock valued at $39,000 after acquiring an additional 1,577 shares during the last quarter. Strs Ohio bought a new stake in shares of Evolent Health during the 1st quarter worth $47,000. Finally, US Bancorp DE grew its holdings in shares of Evolent Health by 291.0% in the 1st quarter. US Bancorp DE now owns 5,153 shares of the technology company’s stock worth $49,000 after acquiring an additional 3,835 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Canaccord Genuity Group decreased their price target on Evolent Health from $16.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 14th. JPMorgan Chase & Co. reduced their price objective on shares of Evolent Health from $13.00 to $7.00 and set an “overweight” rating for the company in a research note on Monday. BMO Capital Markets began coverage on shares of Evolent Health in a research report on Thursday, November 13th. They issued an “outperform” rating and a $7.00 target price on the stock. BTIG Research cut their price target on shares of Evolent Health from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Finally, Oppenheimer reduced their price target on shares of Evolent Health from $18.00 to $12.00 and set an “outperform” rating for the company in a research report on Wednesday, November 12th. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Evolent Health has a consensus rating of “Moderate Buy” and a consensus price target of $12.50.

Evolent Health Stock Performance

Shares of NYSE EVH opened at $3.97 on Wednesday. The business’s 50-day simple moving average is $7.42 and its 200-day simple moving average is $8.78. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.01. Evolent Health, Inc has a 52 week low of $3.66 and a 52 week high of $13.61. The firm has a market cap of $443.50 million, a price-to-earnings ratio of -2.47 and a beta of 0.58.

Evolent Health (NYSE:EVH) last released its quarterly earnings results on Tuesday, June 4th. The technology company reported $0.21 earnings per share (EPS) for the quarter. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. The company had revenue of $427.70 million during the quarter. As a group, equities research analysts expect that Evolent Health, Inc will post 0.08 earnings per share for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.